|Bid||24.55 x 1000|
|Ask||29.60 x 800|
|Day's Range||26.04 - 27.50|
|52 Week Range||22.67 - 41.73|
|Beta (5Y Monthly)||1.08|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 22, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||60.63|
New real-world evidence data on Oxbryta® (voxelotor) from multicenter RETRO Study and new Phase 1 data on GBT601 to be highlighted SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced five abstracts related to its sickle cell disease (SCD) programs will be presented at the European Hematology Association (EHA) 2022 Hybrid Congress. Presentations include new real-world evidence data on Oxbryta® (voxelotor) as well as an
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. Long...
For the quarter, Global Blood Therapeutics' sales hit nearly $55.2 million, representing quite an encouraging improvement over the year-ago quarter's $39 million. Although the revenue figure didn't quite reach the $56.1 million analysts were collectively estimating, Global Blood Therapeutics beat on the bottom line. Global Blood Therapeutics also launched the drug for patients aged 4 to 11.